CERO THERAPEUTICS HOLDINGS I (CERO) Fundamental Analysis & Valuation

NASDAQ:CERO • US71902K4022

Current stock price

0.0951 USD
-1.69 (-94.69%)
At close:
0.12 USD
+0.02 (+26.18%)
After Hours:

This CERO fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. CERO Profitability Analysis

1.1 Basic Checks

  • In the past year CERO has reported negative net income.
  • CERO had a negative operating cash flow in the past year.
CERO Yearly Net Income VS EBIT VS OCF VS FCFCERO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 2024 -5M -10M -15M

1.2 Ratios

  • CERO has a Return On Assets of -675.76%. This is amonst the worse of the industry: CERO underperforms 97.20% of its industry peers.
Industry RankSector Rank
ROA -675.76%
ROE N/A
ROIC N/A
ROA(3y)-69.95%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CERO Yearly ROA, ROE, ROICCERO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 2024 0 200 400 600 800 1K

1.3 Margins

  • CERO does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CERO Yearly Profit, Operating, Gross MarginsCERO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023 2024

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

0

2. CERO Health Analysis

2.1 Basic Checks

  • CERO has more shares outstanding than it did 1 year ago.
  • CERO has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
CERO Yearly Shares OutstandingCERO Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 2024 5M 10M 15M 20M
CERO Yearly Total Debt VS Total AssetsCERO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

  • CERO has an Altman-Z score of -27.63. This is a bad value and indicates that CERO is not financially healthy and even has some risk of bankruptcy.
  • CERO's Altman-Z score of -27.63 is on the low side compared to the rest of the industry. CERO is outperformed by 87.87% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -27.63
ROIC/WACCN/A
WACCN/A
CERO Yearly LT Debt VS Equity VS FCFCERO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 2024 0 50M 100M 150M

2.3 Liquidity

  • A Current Ratio of 0.56 indicates that CERO may have some problems paying its short term obligations.
  • With a Current ratio value of 0.56, CERO is not doing good in the industry: 92.35% of the companies in the same industry are doing better.
  • A Quick Ratio of 0.56 indicates that CERO may have some problems paying its short term obligations.
  • With a Quick ratio value of 0.56, CERO is not doing good in the industry: 91.60% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 0.56
Quick Ratio 0.56
CERO Yearly Current Assets VS Current LiabilitesCERO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 2024 10M 20M 30M 40M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. CERO Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 63.38% over the past year.
EPS 1Y (TTM)63.38%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%71.35%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • Based on estimates for the next years, CERO will show a quite strong growth in Earnings Per Share. The EPS will grow by 14.78% on average per year.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y90.59%
EPS Next 2Y39.36%
EPS Next 3Y24.78%
EPS Next 5Y14.78%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
CERO Yearly Revenue VS EstimatesCERO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2029 2030 2031 2032 50M 100M 150M 200M 250M
CERO Yearly EPS VS EstimatesCERO Yearly EPS VS EstimatesYearly EPS VS Estimates 2025 2026 2027 2028 2029 2030 2031 2032 0 -10 -20 -30

More info and screens

Find the best growth stocksShow best growing peers

1

4. CERO Valuation Analysis

4.1 Price/Earnings Ratio

  • CERO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year CERO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CERO Price Earnings VS Forward Price EarningsCERO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CERO Per share dataCERO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share -50 -100 -150 -200

4.3 Compensation for Growth

  • CERO's earnings are expected to grow with 24.78% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y39.36%
EPS Next 3Y24.78%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. CERO Dividend Analysis

5.1 Amount

  • CERO does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

CERO Fundamentals: All Metrics, Ratios and Statistics

CERO THERAPEUTICS HOLDINGS I

NASDAQ:CERO (10/30/2025, 8:00:00 PM)

After market: 0.12 +0.02 (+26.18%)

0.0951

-1.69 (-94.69%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-15
Earnings (Next)N/A
Inst Owners20.48%
Inst Owner Change-100%
Ins Owners2.67%
Ins Owner Change0%
Market Cap177.84K
Revenue(TTM)N/A
Net Income(TTM)-41.91M
Analysts82.5
Price Target22.95 (24032.49%)
Short Float %0.06%
Short Ratio0
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-50%
PT rev (3m)-50%
EPS NQ rev (1m)83.22%
EPS NQ rev (3m)83.22%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-223.77
EYN/A
EPS(NY)-22.18
Fwd EYN/A
FCF(TTM)-7.15
FCFYN/A
OCF(TTM)-7.15
OCFYN/A
SpS0
BVpS-0.87
TBVpS-0.87
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -675.76%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-69.95%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.56
Quick Ratio 0.56
Altman-Z -27.63
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)63.38%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%71.35%
EPS Next Y90.59%
EPS Next 2Y39.36%
EPS Next 3Y24.78%
EPS Next 5Y14.78%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-54.03%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-720.94%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-720.94%
OCF growth 3YN/A
OCF growth 5YN/A

CERO THERAPEUTICS HOLDINGS I / CERO Fundamental Analysis FAQ

What is the fundamental rating for CERO stock?

ChartMill assigns a fundamental rating of 0 / 10 to CERO.


Can you provide the valuation status for CERO THERAPEUTICS HOLDINGS I?

ChartMill assigns a valuation rating of 1 / 10 to CERO THERAPEUTICS HOLDINGS I (CERO). This can be considered as Overvalued.


Can you provide the profitability details for CERO THERAPEUTICS HOLDINGS I?

CERO THERAPEUTICS HOLDINGS I (CERO) has a profitability rating of 0 / 10.